Reduced DPP4 Binding Confers Resistance to Soluble DPP4 While Preserving MERS-CoV Entry into Cells Expressing High Levels of DPP4

Viruses are masters of adaptation, constantly reshaping themselves to survive in a world that is often trying to stop them. To enter a human cell, a virus must first find a specific door, a protein on the cell's surface that acts as a lock. For the Middle East respiratory syndrome coronavirus, known as MERS-CoV, that door is a protein called DPP4. Scientists have long known that if they can block this door, they can stop the virus from getting inside. One promising strategy involves using a soluble version of this protein—a free-floating piece that floats in the blood and acts like a decoy. This decoy binds to the virus before it reaches a cell, effectively neutralizing it. This approach has shown success in laboratory cultures and animal models, leading researchers to wonder if the body's own natural supply of this decoy protein might help limit the spread of the virus in infected people. However, a critical question remains: can the virus evolve to ignore this decoy and still succeed in its mission?

A team of researchers set out to answer this by watching how the virus changes when forced to live alongside this decoy protein. They did not use the full, dangerous virus in a high-risk setting. Instead, they engineered a harmless model virus, based on a different virus called vesicular stomatitis virus, but equipped with the specific surface spike protein of MERS-CoV. This allowed them to study the entry mechanism safely. They placed this model virus in a culture dish filled with the soluble decoy protein and let it replicate over several rounds. With each generation, the decoy protein acted as a filter, blocking any virus that tried to use the normal path. Only the rare variants that could slip past the decoy survived to reproduce.

After a few rounds of this selection process, the researchers found that the virus had changed. They identified specific mutations in the spike protein, particularly at a position labeled 507, where the amino acid leucine had been replaced by either isoleucine or histidine. These small changes altered the shape of the virus's binding site. The result was a virus that could no longer be easily caught by the soluble decoy protein. When the researchers tested these new variants, they found that the mutations successfully reduced the binding of the decoy, allowing the virus to resist being neutralized. Crucially, these changes did not break the virus's ability to enter cells. In fact, when the researchers tested the mutated virus on cells that had a high density of the natural DPP4 door, the virus entered just as efficiently as the original version. The virus had found a way to dodge the decoy without losing its ability to knock on the right door.

The study also looked at variations that had already been found in real patients, rather than just those created in the lab. Some of these naturally occurring changes at the same position, such as those replacing leucine with arginine or proline, showed an even stronger effect. These natural variants were completely resistant to the soluble decoy protein, yet they remained fully capable of infecting cells that expressed high levels of the receptor. This suggests that the virus does not need to undergo a massive overhaul to escape this type of defense; small, specific tweaks are enough. The researchers observed that while these resistant viruses struggled to enter cells with low levels of the receptor, they thrived in environments where the receptor was abundant.

The findings indicate that the virus possesses a hidden flexibility. It can acquire mutations that lower its affinity for the soluble decoy protein, rendering that therapeutic approach less effective, while still maintaining the strength needed to infect cells where the receptor is plentiful. This means that while soluble DPP4 remains a potential tool for blocking infection, the virus has a clear evolutionary path to bypass it. The study confirms that naturally occurring changes in the virus's genetic code can confer resistance to this specific antiviral strategy, highlighting the importance of understanding how the virus might adapt if such treatments were ever used widely. The virus does not need to abandon its strategy to enter cells; it simply needs to adjust its grip just enough to slip past the floating traps while keeping a firm hold on the real doors.